CARING AMBASSADORS

Empowering People to be Ambassadors of their Own Health Since 1997.

LUNG CANCER PROGRAM


Weekly News

Weekly news updates are currently posted on the Internet site and sent out via e-blast to provide up-to-date information on what has been covered in the news regarding lung cancer in the previous week.  Topics include all stories related to lung cancer as well as personal stories and events.

Week ending October 26, 2014

LungCAN Pressures Medicare To Cover Lung Cancer Screening in New Online Campaign

“On the Medicare issue LungCAN says that failing to cover low-dose CT scans poses a significant problem for two reasons: more than one third of the 46 million Americans on Medicare are current or former smokers for whom the screening is recommended based on their age; and under the Affordable Care Act (ACA), any procedure that is given a B recommendation from the USPSTF has to be covered by private insurers without a copay, yet there is no provision that specifies Medicare needs to comply.”

PARP Inhibitor Shows Potential in Squamous Cell Lung Cancer

“In the study, progression-free survival was improved by 35% and overall survival was extended by 30% with the combination of veliparib with chemotherapy in patients with previously untreated metastatic or advanced NSCLC.”

Tri-Cities Cancer Center program aims to catch lung cancer early

The cancer center’s screening method is effective. A national trial published in 2011 found 20 percent fewer lung cancer deaths among patients screened using CT scans compared to those screened with standard chest X-rays.

Lung cancer can stay hidden for 20+ years

“Survival from lung cancer remains devastatingly low with many new targeted treatments making a limited impact on the disease. By understanding how it develops we’ve opened up the disease’s evolutionary rule book in the hope that we can start to predict its next steps,” said study author Professor Charles Swanton, MD.”

Merck Gets FDA Breakthrough Therapy Designation For Keytruda In Advanced NSCLC

“Merck & Co. Inc. announced that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Keytruda (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with Epidermal Growth Factor Receptor or EGFR mutation-negative, and Anaplastic Lymphoma Kinase or ALK rearrangement-negative non-small cell lung cancer or NSCLC whose disease has progressed on or following platinum-based chemotherapy. This is the second Breakthrough Therapy Designation granted for Keytruda.”

Navigators help patients find way in health care maze

“A patient goes to the emergency room complaining of pneumonia, but a radiology scan indicates he might have a bigger problem like lung cancer.”

 

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)